NA
CBPO

Navellier & Associates’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Navellier & Associates’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,430
Closed -$369K – 329
2016
Q4 		$369K Sell
3,430
-130
-4% -$15.2K 0.06% 199
2016
Q3 		$443K Buy
3,560
+15
+0.4% +$1.77K 0.06% 166
2016
Q2 		$377K Sell
3,545
-204
-5% -$23.7K 0.06% 160
2016
Q1 		$429K Sell
3,749
-4,771
-56% -$560K 0.06% 139
2015
Q4 		$1.21M Sell
8,520
-6,433
-43% -$743K 0.13% 70
2015
Q3 		$1.34M Sell
14,953
-773
-5% -$81.6K 0.14% 75
2015
Q2 		$1.81M Buy
15,726
+760
+5% +$79.8K 0.16% 76
2015
Q1 		$1.43M Buy
14,966
+3,817
+34% +$286K 0.13% 86
2014
Q4 		$750K Buy
+11,149
New +$691K 0.04% 140
2014
Q2 		– Sell
-6,273
Closed -$218K – 367
2014
Q1 		$218K Buy
+6,273
New +$200K 0.01% 303

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HIM
Hermes Investment Management London Uk, United Kingdom $7.52B AUM 20.67% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Navellier & Associates's CBPO Position: Q1 2017 in Review

Navellier & Associates sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2017, closing a stake of 3,430 shares — an estimated $369K sold.

Navellier & Associates first reported a position in CBPO in Q1 2014 and held it in 10 quarters. The position peaked at $1.81M in Q2 2015. 137 funds tracked by Wall St. Rank hold CBPO as of Q1 2017.

  • Navellier & Associates reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2017 after selling out during the quarter.
  • Navellier & Associates sold 3,430 China Biologic Products Holdings, Inc. shares in Q1 2017, an estimated $369K.
  • Navellier & Associates first reported a position in China Biologic Products Holdings, Inc. in Q1 2014 and held it in 10 quarters.
  • Navellier & Associates's China Biologic Products Holdings, Inc. position peaked at $1.81M in Q2 2015.
  • 137 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2017.

Based on Navellier & Associates's 13F filing for Q1 2017, filed 21 Apr 2017.